File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients

TitleBreakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients
Authors
KeywordsBreakthrough invasive fungal infections
Echinocandin
Issue Date2014
Citation
Annals of Hematology, 2014, v. 93, n. 3, p. 493-498 How to Cite?
AbstractThe frequency of breakthrough invasive fungal diseases (IFDs) during echinocandin therapy is unclear. We retrospectively analyzed 534 hematologic patients treated with echinocandin (caspofungin, N = 55; micafungin, N = 306; anidulafungin, N = 173). Four proven IFDs were found, caused by Candida parapsilosis (N = 2), C. parapsilosis and Candida glabrata (N = 1), and Fusarium species (N = 1). Four cases of possible IFDs were observed, all showing pulmonary infection. One case showed features suggestive of hepatosplenic candidiasis. Six of these eight cases had previously received the purine analog clofarabine. Breakthrough IFD during echinocandin treatment occurred infrequently (1.5 %), caused predominantly by Candida species. Clofarabine usage was an important risk factor. © 2013 Springer-Verlag Berlin Heidelberg.
Persistent Identifierhttp://hdl.handle.net/10722/199943
ISSN
2015 Impact Factor: 3.022
2015 SCImago Journal Rankings: 1.117
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, Thomas S Y-
dc.contributor.authorGill, Harinder-
dc.contributor.authorHwang, Yuyan-
dc.contributor.authorSim, Joycelyn-
dc.contributor.authorTse, AlancT-
dc.contributor.authorLoong, Florence-
dc.contributor.authorKhong, Pek Lan-
dc.contributor.authorTse, Eric-
dc.contributor.authorLeung, Anska Y H-
dc.contributor.authorChim, James C S-
dc.contributor.authorLie, Albert-
dc.contributor.authorKwong, Yok Lam-
dc.date.accessioned2014-07-26T23:10:56Z-
dc.date.available2014-07-26T23:10:56Z-
dc.date.issued2014-
dc.identifier.citationAnnals of Hematology, 2014, v. 93, n. 3, p. 493-498-
dc.identifier.issn0939-5555-
dc.identifier.urihttp://hdl.handle.net/10722/199943-
dc.description.abstractThe frequency of breakthrough invasive fungal diseases (IFDs) during echinocandin therapy is unclear. We retrospectively analyzed 534 hematologic patients treated with echinocandin (caspofungin, N = 55; micafungin, N = 306; anidulafungin, N = 173). Four proven IFDs were found, caused by Candida parapsilosis (N = 2), C. parapsilosis and Candida glabrata (N = 1), and Fusarium species (N = 1). Four cases of possible IFDs were observed, all showing pulmonary infection. One case showed features suggestive of hepatosplenic candidiasis. Six of these eight cases had previously received the purine analog clofarabine. Breakthrough IFD during echinocandin treatment occurred infrequently (1.5 %), caused predominantly by Candida species. Clofarabine usage was an important risk factor. © 2013 Springer-Verlag Berlin Heidelberg.-
dc.languageeng-
dc.relation.ispartofAnnals of Hematology-
dc.subjectBreakthrough invasive fungal infections-
dc.subjectEchinocandin-
dc.titleBreakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00277-013-1882-2-
dc.identifier.pmid23949318-
dc.identifier.scopuseid_2-s2.0-84894305474-
dc.identifier.hkuros229610-
dc.identifier.hkuros225446-
dc.identifier.volume93-
dc.identifier.issue3-
dc.identifier.spage493-
dc.identifier.epage498-
dc.identifier.eissn1432-0584-
dc.identifier.isiWOS:000331044600016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats